Sangamo Biosciences, Inc. (NASDAQ:SGMO)

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) made a handy gain to start out the week after the firm, in conjunction with Pfizer Inc. (NYSE: PFE), announced updated results from a mid-stage ...
Read Full Story »

What’s Next for Sangamo After This Hemophilia Study

Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer Inc. (NYSE: PFE). The Phase 1/2 ...
Read Full Story »

Why Pfizer Is Getting Deeper Into Gene Therapy

Pfizer Inc. (NYSE: PFE) is getting deeper into gene therapy. The U.S. drug giant has acquired a 15% stake in Vivet Therapeutics. On top of the investment in the French ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alphabet, Amarin, Apple, AutoNation, BlackRock, E*Trade, Etsy, Kellogg, PG&E and More

Stocks were indicated to open marginally higher on Wednesday, but this is a day after the gap-up open failed to hold by the end of Tuesday and after a 602 ...
Read Full Story »

Top Analyst Upgrades and Downgrades: ArcelorMittal, Barclays, Cree, Ctrip.com, Michael Kors, PVH, Skyworks, TripAdvisor, YRC Worldwide, Yelp and More

Stocks were indicated to open lower on Friday. While there has been a big bounce off last week's lows, investors have seen lower upside after buying immediately after the big ...
Read Full Story »

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

When it comes to mid-cap and small-cap biotech stocks, there are two ways shareholders get rewarded ahead of or after big drug development news. One is that the company grows ...
Read Full Story »

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares saw a solid gain early Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences ...
Read Full Story »

Sangamo Jumps on Newest Pfizer Collaboration

Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer Inc. (NYSE: PFE) for ...
Read Full Story »

30 Big Biotech Events Coming in 2018

Over the past year, biotech companies have more or less kept pace with the markets, but they have the potential to break out in 2018. While they have been the ...
Read Full Story »

The 11 Biggest and Best Analyst Upgrades of June

With traditional Dow Jones Industrial Average and S&P stocks, analysts are currently assigning targets with 8% to 15% upside. Any rational investor understands that there is a much larger risk ...
Read Full Story »

Jefferies Sees 6 Biotechs as Undervalued With Massive Upside

Biotech companies are known for having a high-risk high-reward relationship. The health care sector as a whole has been very positive for investors over the past year, leading some analysts ...
Read Full Story »

7 Speculative Biotech and Pharma Stocks That Could Still Double (or More)

As the markets roll into summer, the markets are close to all-time highs and investors are wondering how they should be positioned as the bull market is now over eight ...
Read Full Story »

Why Sangamo Therapeutics Is Surging

Sangamo Therapeutics Inc. (NASDAQ: SGMO) saw its shares skyrocket early on Thursday after a critical business update. Although the company did recently report its first-quarter results, this is not what’s ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades for Tuesday: Baker Hughes, Brocade, CenturyLink, Chevron, Juniper, National Oilwell Varco and Many More

Stocks were indicated marginally higher on Tuesday, but it feels like the market is just looking for direction ahead of the Federal Reserve's FOMC meeting and ahead of next week's ...
Read Full Story »
thumbs up and down

Top Analyst Upgrades and Downgrades: Apollo Global, ADM, Celgene, Total, Whole Foods, Targa Resources and More

Stocks were indicated higher on Thursday after the Bank of England cut interest rates for the first time in seven years and engaged in more aggressive quantitative easing than expected. ...
Read Full Story »